 |
|
Comparison of Sustained-Release Nifedipine and Temperature Biofeedback for Treatment of Primary Raynaud Phenomenon
Results From a Randomized Clinical Trial With 1-Year Follow-up
Raynaud's Treatment Study Investigators
Arch Intern Med. 2000;160:1101-1108.
Background The efficacy and safety of sustained-release nifedipine for the treatment of primary Raynaud phenomenon (RP) has not previously been demonstrated by a randomized, controlled trial. Temperature biofeedback has been studied in patients with primary RP but not in a large multicenter controlled trial or compared with nifedipine therapy.
Objective To evaluate and compare the effectiveness of sustained-release nifedipine and temperature biofeedback for the treatment of primary RP.
Participants and Methods This is a randomized, controlled clinical trial, double-masked for drug and placebo but not masked for temperature and control biofeedback. It included 313 persons with primary RP as defined by medical history, physical examination findings, normal nailfold capillaries, and a history of 2 or more attacks per day during the previous cold season. Participants were randomized to 1 of 4 treatment groups: (1) sustained-release nifedipine, (2) pill placebo, (3) temperature biofeedback, or (4) control (electromyographic) biofeedback. The primary outcome measure was self-reported, color chart–verified RP attacks during 1 winter month approximately 1 year after initiation of treatment. Secondary outcome measures included verified attacks at 2 months, all attacks at 2 months and 1 year, and quality of life.
Results Nifedipine-treated participants showed a 66% reduction in verified attacks compared with placebo recipients (P<.001); temperature biofeedback training did not reduce attacks significantly compared with control biofeedback (P=.37). Comparison of nifedipine and temperature biofeedback treatments favored nifedipine use (P=.08); similar results were obtained for the secondary end points. Adverse effects resulted in discontinuation of nifedipine treatment in 15% of participants.
Conclusions Temperature biofeedback is not better than its control treatment and is inferior to sustained-release nifedipine for treating primary RP, whereas sustained-release nifedipine is a safe and effective treatment for this disease.
This work was supported by contracts HC-25119, HC-25120, HC-25121, HC-25122, HC-25123, and HC-25127 from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(8):1206-1207.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysis
Malenfant et al.
Rheumatology (Oxford) 2009;48:791-795.
ABSTRACT
| FULL TEXT
Clinical trials studying pharmacotherapy and psychological treatments alone and together
Haythornthwaite
Neurology 2005;65:S20-S31.
ABSTRACT
| FULL TEXT
Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis
Thompson and Pope
Rheumatology (Oxford) 2005;44:145-150.
ABSTRACT
| FULL TEXT
Raynaud's Phenomenon
Wigley
NEJM 2002;347:1001-1008.
FULL TEXT
Treatment of Scleroderma
Sapadin and Fleischmajer
Arch Dermatol 2002;138:99-105.
ABSTRACT
| FULL TEXT
Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling
Maricq et al.
Vasc Med 2000;5:135-140.
ABSTRACT
General Medicine: Nifedipine Better Than Biofeedback for Raynaud's Phenomenon
JWatch Psychiatry 2000;2000:18-18.
FULL TEXT
Nifedipine Better Than Biofeedback for Raynaud's Phenomenon
Journal Watch Dermatology 2000;2000:15-15.
FULL TEXT
Nifedipine Better Than Biofeedback for Raynaud's Phenomenon
JWatch General 2000;2000:3-3.
FULL TEXT
|
